PharmacyCodes



Clomifene citrate (JP14) en es it fr

Clomifene citrate (JP14) Brand names, Clomifene citrate (JP14) Analogs

Clomifene citrate (JP14) Brand Names Mixture

  • No information avaliable

Clomifene citrate (JP14) Chemical_Formula

C26H28ClNO

Clomifene citrate (JP14) RX_link

http://www.rxlist.com/cgi/generic/clomiph.htm

Clomifene citrate (JP14) fda sheet

Clomifene citrate (JP14) msds (material safety sheet)

Clomifene citrate (JP14) Synthesis Reference

No information avaliable

Clomifene citrate (JP14) Molecular Weight

405.959 g/mol

Clomifene citrate (JP14) Melting Point

No information avaliable

Clomifene citrate (JP14) H2O Solubility

Slightly soluble

Clomifene citrate (JP14) State

Solid

Clomifene citrate (JP14) LogP

7.496

Clomifene citrate (JP14) Dosage Forms

Capsule; Liquid; Powder; Tablet; Tablet (effervescent)

Clomifene citrate (JP14) Indication

Used mainly in female infertility due to anovulation (e.g. due to polycystic ovary syndrome). In some countries, it is also registered for use in men.

Clomifene citrate (JP14) Pharmacology

Clomifene (previously clomiphene) is an orally administered, non steroidal, ovulatory stimulant that acts as a selective estrogen receptor modulator (SERM). Clomifene can lead to multiple ovulation, and hence increasing the risk of twins. In comparison to purified FSH, the rate of ovarian hyperstimulation syndrome is low. There may be an increased risk of ovarian cancer, and weight gain. Clomifene is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix. It may compete with estrogen for estrogen-receptor-binding sites and may delay replenishment of intracellular estrogen receptors. Clomifene initiates a series of endocrine events culminating in a preovulatory gonadotropin surge and subsequent follicular rupture. The first endocrine event in response to a course of clomifene therapy, is an increase in the release of pituitary gonadotropins. This initiates steroidogenesis and folliculogenesis resulting in growth of the ovarian follicle and an increase in the circulating level of estradiol. Following ovulation, plasma progesterone and estradiol rise and fall as they would in a normal ovulatory cycle.

Clomifene citrate (JP14) Absorption

Based on early studies with 14 C-labeled clomifene, the drug was shown to be readily absorbed orally in humans.

Clomifene citrate (JP14) side effects and Toxicity

The acute oral LD50 of clomifene is 1700 mg/kg in mice and 5750 mg/kg in rats. The toxic dose in humans is not known. Toxic effects accompanying acute overdosage of clomifene have not been reported. Signs and symptoms of overdosage as a result of the use of more than the recommended dose during clomifene therapy include nausea, vomiting, vasomotor flushes, visual blurring, spots or flashes, scotomata, ovarian enlargement with pelvic or abdominal pain.

Clomifene citrate (JP14) Patient Information

No information avaliable

Clomifene citrate (JP14) Organisms Affected

Humans and other mammals